Domperidone-associated sudden cardiac death in the general population and implications for use in patients undergoing hemodialysis: A literature review

Canadian Journal of Hospital Pharmacy

Volumn 67, Issue 6, 2014, Pages 441-446

  Makari, Joy ^a,b   Cameron, Karen ^c   Battistella, Marisa ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cardiac arrhythmia; Dialysis; Domperidone; Sudden cardiac death

Indexed keywords

DOMPERIDONE;

CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG SAFETY; DRUG USE; END STAGE RENAL DISEASE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEMODIALYSIS PATIENT; HUMAN; OBSERVATIONAL STUDY; REVIEW; STOMACH PARESIS; SUDDEN CARDIAC DEATH;

EID: 84928687030     PISSN: 00084123     EISSN: 19202903     Source Type: Journal    
DOI: 10.4212/cjhp.v67i6.1407     Document Type: Review

References (22)

1. Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol. 2012;23(12):1929-39.
2. Bignotto LH, Kallds ME, Djouki RJT, Sassaki MM, Voss GO, Soto CL, et al. Electrographic findings in chronic hemodialysis patients. J Bras Nefrol. 2012;34(3):235-42.
3. Centers for Disease Control and Prevention. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes-United States and Puerto Rico, 1996-2007. MMWR Morb Mortal Wkly Rep. 2010;59(42):1361-6.
4. Alam U, Asghar O, Malik RA. Diabetic gastroparesis: therapeutic options. Diabetes Ther. 2010;1(1):32-43.
5. Hejazi RA, McCallum RW, Sarosiek I. Isokinetics in diabetic gastroparesis. Curr Gastroenterol Rep. 2012;14(4):297-305.
6. Domperidone maleate - association wirh serious abnormal heart rhythms and sudden death (cardiac arrest) - for health professionals. Ottawa (ON): Health Canada; 2012 Mar 2 [cited 2014 Sep 28]. Available from: www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/15857a-eng.php
7. European Medicines Association, Pharmacovigilance Working Party. Annex 3: Dompetidone - risk of cardiac disorders. In: Report of October 2011 plenary meeting. London (UK): European Medicines Association; 2011 Oct 27 [cited 2014 Sep 28]. p. 10-11. Available from: www.ema.europa.eu/docs/en-GB/documenr-library/Report/2011/10/WC500117061.pdf
8. Safety alerts for human medical products: domperidone. Food and Drug Administration (US); 2004 [updated 2013 Aug 21; cited 2014 Sep 28]. Available from: www.fda.gov/Safety/MedWatch/Safetylnformation/SafetyAlertsforHumanMedicalProducts/ucm154914.htm
9. Noord CV, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010; 33(11): 1003-14.
10. Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010;19(9):881-8.
11. Jolly K, Gammage MD, Cheng KK, Bradburn P, Banting MV, Langman MJ. Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol. 2009;68(5):743-51.
12. Straus SM, Sturkenboom MC, Bleumink GS, Dieieman JP, van der Lei J, de Graeff PA, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26(19):2007-12.
13. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol. 2005;26(5):720-3.
14. Djeddi D, Kongolo G, Lefaix C, Mounard J, Léké A. Effect of dompetidone on QT interval in neonates. J Pediatr. 2008;153(5):663-6.
15. Digby G, Machaalany J, Malik P, Methot M, Simpson CS, Redfearn D, et al. Multifactorial QT interval prolongation. Cardiol J. 2010; 17(2): 184-8.
16. Bruera E, Villamayor R, Roca E, Barugel M, Tronge J, Chacon R. Q-T interval prolongation and ventricular fibrillation with i.v. domperidone. Cancer Treat Rep. 1986;70(4):545-6.
17. Osborne RJ, Slevin MI, Hunter RW, Hamer J. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum Toxicol. 1985;4(6):617-26.
18. Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5(3):257-62.
19. Ciaassen S, Zünkler BJ. Comparison of the effects of metoclopramide and domperidone on HF.RG channels. Pharmacology. 2005;74(1):31-6.
20. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harrii D, Hylek EM, Phillips B, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 2006; 129(1): 174-81.
21. Hasnain M, Vieweg WVR. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887-920.
22. Domperidone maleate [product information]. In: Compendium of pharmaceuticals and specialties [electronic version]. Ottawa (ON): Canadian Pharmacists Association; 2012.